Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Consistency of Hib-MenAC mixed with Tritanrix-HepB in healthy infants
NCT00197275Phase 3Completed
- Sponsor
- GSK
- Start
- Feb 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Hib + MenAC in Haemophilus influenzae type b infection (Hib), Meningococcal disease serogroup A and Meningococcal disease serogroup C (MenC) (4 arms), sponsored by GSK. Primary endpoint: Immune response to vaccine antigens. Started Feb 2006; status: completed.
02
Drugs
Hib + MenAC
03
Conditions
Haemophilus influenzae type b infection (Hib)Meningococcal disease serogroup AMeningococcal disease serogroup C (MenC)
Beyond the preview
Go deeper on NCT00197275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00197275.